Merkel cell carcinoma: An update and immunotherapy

Hiroshi Uchi

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Merkel cell carcinoma (MCC) is a rare but aggressive skin cancer with frequent metastasis and death. MCC has a mortality rate of 30%, making it more lethal than malignant melanoma, and incidence of MCC has increased almost fourfold over the past 20 years in the USA. MCC has long been considered to be an immunogenic cancer because it occurs more frequently in immunosuppressed patients from organ transplant and HIV infection than in those with immunocompetent. Chronic UV light exposure and clonal integration of Merkel cell polyomavirus (MCPyV) are two major causative factors of MCC. Approximately 80% of MCC are associated with MCPyV, and T cells specific for MCPyV oncoproteins are present in the blood and tumors of patients. Several studies have shown that a subset of MCCs express PD-1 on tumor-infiltrating lymphocytes and express PD-L1 on tumor cells, which suggests an endogenous tumor-reactive immune response that might be unleashed by anti-PD-1 or anti-PD-L1 drugs.

Original languageEnglish
Article number48
JournalFrontiers in Oncology
Volume8
Issue numberMAR
DOIs
Publication statusPublished - Mar 6 2018

Fingerprint

Merkel Cell Carcinoma
Immunotherapy
Merkel cell polyomavirus
Neoplasms
Tumor-Infiltrating Lymphocytes
Oncogene Proteins
Skin Neoplasms
Ultraviolet Rays
HIV Infections
Melanoma
Neoplasm Metastasis
T-Lymphocytes
Transplants
Mortality
Incidence
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Merkel cell carcinoma : An update and immunotherapy. / Uchi, Hiroshi.

In: Frontiers in Oncology, Vol. 8, No. MAR, 48, 06.03.2018.

Research output: Contribution to journalReview article

Uchi, Hiroshi. / Merkel cell carcinoma : An update and immunotherapy. In: Frontiers in Oncology. 2018 ; Vol. 8, No. MAR.
@article{e374c87f735f44019e597a17a51d82d3,
title = "Merkel cell carcinoma: An update and immunotherapy",
abstract = "Merkel cell carcinoma (MCC) is a rare but aggressive skin cancer with frequent metastasis and death. MCC has a mortality rate of 30{\%}, making it more lethal than malignant melanoma, and incidence of MCC has increased almost fourfold over the past 20 years in the USA. MCC has long been considered to be an immunogenic cancer because it occurs more frequently in immunosuppressed patients from organ transplant and HIV infection than in those with immunocompetent. Chronic UV light exposure and clonal integration of Merkel cell polyomavirus (MCPyV) are two major causative factors of MCC. Approximately 80{\%} of MCC are associated with MCPyV, and T cells specific for MCPyV oncoproteins are present in the blood and tumors of patients. Several studies have shown that a subset of MCCs express PD-1 on tumor-infiltrating lymphocytes and express PD-L1 on tumor cells, which suggests an endogenous tumor-reactive immune response that might be unleashed by anti-PD-1 or anti-PD-L1 drugs.",
author = "Hiroshi Uchi",
year = "2018",
month = "3",
day = "6",
doi = "10.3389/fonc.2018.00048",
language = "English",
volume = "8",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",
number = "MAR",

}

TY - JOUR

T1 - Merkel cell carcinoma

T2 - An update and immunotherapy

AU - Uchi, Hiroshi

PY - 2018/3/6

Y1 - 2018/3/6

N2 - Merkel cell carcinoma (MCC) is a rare but aggressive skin cancer with frequent metastasis and death. MCC has a mortality rate of 30%, making it more lethal than malignant melanoma, and incidence of MCC has increased almost fourfold over the past 20 years in the USA. MCC has long been considered to be an immunogenic cancer because it occurs more frequently in immunosuppressed patients from organ transplant and HIV infection than in those with immunocompetent. Chronic UV light exposure and clonal integration of Merkel cell polyomavirus (MCPyV) are two major causative factors of MCC. Approximately 80% of MCC are associated with MCPyV, and T cells specific for MCPyV oncoproteins are present in the blood and tumors of patients. Several studies have shown that a subset of MCCs express PD-1 on tumor-infiltrating lymphocytes and express PD-L1 on tumor cells, which suggests an endogenous tumor-reactive immune response that might be unleashed by anti-PD-1 or anti-PD-L1 drugs.

AB - Merkel cell carcinoma (MCC) is a rare but aggressive skin cancer with frequent metastasis and death. MCC has a mortality rate of 30%, making it more lethal than malignant melanoma, and incidence of MCC has increased almost fourfold over the past 20 years in the USA. MCC has long been considered to be an immunogenic cancer because it occurs more frequently in immunosuppressed patients from organ transplant and HIV infection than in those with immunocompetent. Chronic UV light exposure and clonal integration of Merkel cell polyomavirus (MCPyV) are two major causative factors of MCC. Approximately 80% of MCC are associated with MCPyV, and T cells specific for MCPyV oncoproteins are present in the blood and tumors of patients. Several studies have shown that a subset of MCCs express PD-1 on tumor-infiltrating lymphocytes and express PD-L1 on tumor cells, which suggests an endogenous tumor-reactive immune response that might be unleashed by anti-PD-1 or anti-PD-L1 drugs.

UR - http://www.scopus.com/inward/record.url?scp=85042937704&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042937704&partnerID=8YFLogxK

U2 - 10.3389/fonc.2018.00048

DO - 10.3389/fonc.2018.00048

M3 - Review article

AN - SCOPUS:85042937704

VL - 8

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

IS - MAR

M1 - 48

ER -